The interaction of human and bovine serum proteins with CYP3A in human liver microsomes: Inhibition of testosterone 6β-hydroxylation by albumin, α-globulins, α1-acid glycoprotein and γ-globulins

Toxicology Letters

Volumn 136, Issue 1, 2002, Pages 33-41

  Matsumoto, Satoshi ^a   Ding, Li R ^a   Ishii, Mikio ^a   Fischer, Nancy E ^a   Inaba, Tadanobu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

1 AGP; Albumin; CYP3A; Globulins; Testosterone

Indexed keywords

ALPHA GLOBULIN; BOVINE SERUM ALBUMIN; CYTOCHROME P450 3A4; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN; ISOENZYME; OROSOMUCOID; TESTOSTERONE;

ARTICLE; CASE REPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME; METABOLISM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION;

ALPHA-GLOBULINS; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOOD PROTEINS; CATTLE; CHROMATOGRAPHY, THIN LAYER; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; GAMMA-GLOBULINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INDICATORS AND REAGENTS; KINETICS; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; PROTEIN BINDING; SERUM ALBUMIN; SERUM ALBUMIN, BOVINE; STEROID HYDROXYLASES;

BOVINAE;

EID: 0037111110     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(02)00285-0     Document Type: Article

References (16)

1. Baba T., Touchi A., Yamaguchi Y., Ito K., Yamazoe Y., Sugiyama Y., Ohno Y. Can in vitro metabolism and enzyme inhibition be explained by unbound drug concentration? Drug. Met. Rev. 32:(Suppl. 2):2000;222.
2. Bowman B.H. Hepatic Plasma Proteins: Mechanisms of Function and Regulation. 1993;Academic Press, New York.
3. Carlile D.J., Hakooz N., Bayliss M.K., Houston J.B. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br. J. Clin. Pharmacol. 47:1999;625-635.
4. Inaba T., Fischer N.E., Riddick D.S., Stewart D.J., Hidaka T. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol. Lett. 93:1997;215-219.
5. Ishii M., Xu B.Q., Ding L.R., Fischer N.E., Inaba T. Interaction of plasma proteins with cytochromes P450 mediated metabolic reactions: inhibition by human serum albumin and α-globulins of the debrisoquine 4-hydroxylation (CYP2D) in liver microsomes of human, hamster and rat. Toxicol. Lett. 119:2001;219-225.
6. Ito K., Iwatsubo T., Kanamitsu S., Nakajima Y., Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism together with binding and transport. Ann. Rev. Pharmacol. Toxicol. 38:1998;461-499.
7. Kenworthy K.E., Bloomer J.C., Clarke S.E., Houston J.B. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 48:1999;716-727.
8. Kurihara N. Effects of added albumin on the kinetic isotope effect observed in the microsomal oxidative demethylation of the methoxy group. Biochem. Biophys. Res. Commun. 195:1993;47-52.
9. Levy R., Qiu W., Yao C., Mather G., Lharasch E., Kunze K., Trager W., Carlson S., Ragueneau-Majelessi I. Relevance of the free drug hypothesis in the prediction of inhibition drug interactions from in vitro. Drug. Metab. Rev. 32:(Suppl. 2):2000;154.
10. Lu P., Lin Y., Rodrigues A.D., Rushmore T.H., Baillie T.A., Shou M. Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4. Drug. Metab. Dispos. 29:2001;1473-1479.
11. m values: implications for clinical correlation. J. Pharmacol. Exp. Ther. 282:1997;391-396.
12. Masuda M., Kishimoto D., Kurihara N. Rate parameter changes by added albumin in the microsomal oxidative demethylation of deuteriated and non-deuteriated 4-methoxyanisol. Biosci. Biotech. Biochem. 60:1996;806-810.
13. Peters T. Jr. All About Albumin: Biochemistry, Genetics and Medical Applications. 1996;Academic Press, New York.
14. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with the liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:1994;414-423.
15. Shou M., Lu T., Krausz K.W., Sai Y., Yang T., Korzekwa K.R., Gonzalez F.J., Gelboin H.V. Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. Eur. J. Pharmacol. 394:2000;199-209.
16. Sumida A., Kinoshita K., Fukuda T., Matsuda H., Yamamoto I., Inaba T., Azuma J. Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochem. Biophys. Res. Commun. 262:1999;499-503.